Amendments to the Specification

Page 23, line 26 to page 25, line 18, please rewrite as follows:

[0042] As a carrier component or additive used for the liquid preparation (including a jelly, a gumi, and the like), there may be mentioned an aqueous solvent (including a purified water such as distilled water, an alcoholic solvent such as ethanol, glycerin, propylene glycol, a polyethylene glycol (e.g., macrogol), in addition, a physiological saline, a Ringer's solution, and the like), an oily solvent (including a vegetable oil such as olive oil, sesame oil, cottonseed oil, or corn oil; and tricaprylin), a gel base or gelatinizing agent (e.g., a natural gum or polysaccharide (e.g., a pectin, a locust bean gum, a gum Arabic, a tragacanth gum, sodium alginate, an agar, a carrageenan, a hyaluronic acid, and a chondroitin sulfate), a cellulose derivative (e.g., cellulose ethers exemplified in the paragraph of the binder), a synthetic polymer (e.g., synthetic polymers (including a vinyl polymer) exemplified in the paragraph of the binder, in addition, a polyethylene glycol, an acrylic acid polymer such as a (meth)acrylic acid copolymer), a dispersant (e.g., Tween 80, a polyethylene glycol, a carboxymethyl cellulose, and sodium alginate), a suspension (e.g., a polysaccharide such as a gum Arabic or a locust bean gum, a cellulose ~~ester~~ ether such as a carboxymethyl cellulose, and a nonionic surfactant), the above-exemplified surfactants, an emulsifier, a solubilizing agent, a solubilizer (including sodium salicylate, and sodium acetate), an isotonizing agent (including sodium chloride, glycerine, sorbitol, glucose, and an invert sugar), a viscosity adjuster (e.g., the above-exemplified thickeners), a preservative or antiseptic agent (e.g., methyl paraben, propyl paraben, benzyl alcohol, chlorobutanol, phenol, sodium benzoate, p-hydroxybenzoate ester, and benzalkonium chloride), an antioxidant, a stabilizer (including a human serum albumin), the above-exemplified saccharides, a pH control agent (including an acid component such as carbonic acid, phosphoric acid, citric acid, or hydrochloric acid; and a base component such as sodium hydroxide), a buffer (e.g., an organic acid-series buffer such as sodium acetate, citric acid, sodium citrate, potassium bitartrate, or sodium bitartrate; a phosphate-series buffer such as sodium dihydrogen phosphate or potassium dihydrogen phosphate; a boric acid-series buffer such as boric acid or borax (or sodium borate)), and others. Incidentally, the liquid preparation such as an injection may contain a soothing agent (including benzalkonium chloride, procaine hydrochloride, etc.) as an additive.

Page 28, lines 3-5, please rewrite as follows:

(a) Hypertension

Systolic blood pressure ≥ 160 mmHg or diastolic phase of uterine contraction ≥ 90 ~~nnHg~~ mmHg

Page 28, line 18 to page 29, line 22, please rewrite as follows:

[0048] Further, more specifically, the pharmaceutical composition of the present invention may be used as an agent for the prophylaxis and/or treatment of the metabolic syndrome, in addition, for example, symptoms such as diabetes (e.g., Type 1 diabetes, Type 2 diabetes, and pregnancy diabetes), diabetes complications (e.g., retinopathy, nephropathy, diabetic neuropathy, and macroangiopathy), a symptom of hyperglycemia after a meal in diabetics, impaired glucose tolerance (IGT), ~~an agent for suppressing~~ development of impaired glucose tolerance into diabetes, decrease of glucose tolerance, a cardiovascular disease [e.g., hyperlipidemia (e.g., hypertriglyceridemia, hypercholesterolemia, and hypo-high-density-lipoproteinemia), and hypertension], hyperinsulinemia, coronary and cerebrovascular disorder, hyperammonemia, hyperammonemia, hyperuricemia, obesity or a complication thereof, a bone metabolism disorder (e.g., osteoporosis, and osteopenia), fatty liver, hepatitis, dumping syndrome, and glycogenosis. Incidentally, the pharmaceutical composition of the present invention is suitable for the prophylaxis and/or treatment of at least one symptom selected from above symptoms, and also is useful as an agent for the prophylaxis and/or treatment of a plurality of symptoms. In particular, the pharmaceutical composition of the present invention is useful as an agent for the prophylaxis and/or treatment of at least one symptom selected from the group consisting of metabolic syndrome, hyperlipemia, diabetes, diabetes complications, a symptom of hyperglycemia after a meal in diabetics, impaired glucose tolerance (IGT), decrease of glucose tolerance, hypertension, hyperinsulinemia, hyperammonemia, obesity or a complication thereof, fatty liver, and hepatitis.